Clinical Trials Logo

Filter by:
NCT ID: NCT04440371 Active, not recruiting - Clinical trials for Vitiligo, Generalized

Phototherapy Combination With Topicals in Vitiligo

NBUVB
Start date: June 21, 2020
Phase: N/A
Study type: Interventional

Patients will be included in a randomized controlled clinical trial, will enroll only adult vitiligo patients with surface area of at least 10% who are being followed in the outpatient dermatology clinics of King Abdullah University Hospital (KAUH) and are planned to start on phototherapy Narrow Band Ultraviolet light B (NBUVB), regardless if they have previous treatment for their disease, one month wash off period will be given for patients who are already on phototherapy or other treatments for vitiligo.

NCT ID: NCT04435912 Completed - Blood Pressure Clinical Trials

Hydrocortisone Per-treatment Decrease Side Effects of Protamine Sulfate

Start date: July 4, 2019
Phase: Early Phase 1
Study type: Interventional

This study aims to compare the hemodynamic parameters within and between patients who received Protamine Sulfate (PS) with Hydrocortisone (HC) vs. Protamine Sulfate alone during cardiac surgeries.

NCT ID: NCT04424732 Recruiting - Clinical trials for Breast Neoplasm Malignant Female

SBRT for Breast Cancer Oligometastases

Start date: June 1, 2020
Phase: N/A
Study type: Interventional

This is a prospective data collection of treatment outcome for newly diagnosed oligometastatic breast cancers with 1-3 bone metastases. Eligible patients will be identified from the weekly Breast MDC. Patients will receive the recommended systemic and local treatment (including metastases directed SBRT) according to our clinical practice guidelines.Patients will be followed according to our routine with clinical and radiologic assessment. It is preferred that the same imaging method that was used to originally detect the metastases be used in follow-up assessments. The first imaging for SBRT sites will be three months post SBRT and every three months for the first year, every 6 months for the second year, then annually. Response and progression for these metastases will be evaluated using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Changes in the largest diameter (unidimensional measurement) of the tumor lesions is used in the RECIST criteria. If functional imaging (bone scan, PET) were used at staging, changes in the uptake will be used in follow up scans to determine response to treatment and progression. As for SBRT related morbidities, we will use the Common Terminology Criteria for Adverse Events (CTCAE v5) for toxicity reporting and scoring.

NCT ID: NCT04416620 Completed - Clinical trials for Polycystic Ovary Syndrome

The Impact of a Pharmaceutical Care Model on Improving Polycystic Ovary Syndrome

Start date: February 1, 2017
Phase: N/A
Study type: Interventional

The primary aim of this study was to estimate the prevalence of anxiety disorder and depression amongst Syrian and Jordanian women who are suffering from PCOS in Damascus and Amman. The secondary aim was to assess the effectiveness of a PCOS pharmaceutical care service on selected patient's biochemical parameters, QOL, anxiety, and depression scale. The third aim is to identify the factors associated with QOL, anxiety and depression scores' change across the study. Null Hypothesis (research hypothesis): The intervention of PCOS pharmaceutical care service will lead to no significant differences in patient's depression, anxiety, QOL, and some biochemical parameters in comparison to females who will not receive this intervention in both Syria and Jordan. Alternative Hypothesis (research hypothesis): The intervention of PCOS pharmaceutical care service will have a significant impact on patient's depression, anxiety, QOL, and some biochemical parameters in comparison to patients who will not receive this intervention in both Syria and Jordan.

NCT ID: NCT04378205 Completed - Clinical trials for Orthodontic Appliance

Pulpal Blood Flow Changes Using SuperElastic 0.018-inch Nickel Titanium

Start date: September 1, 2018
Phase: N/A
Study type: Interventional

to record pulpal blood flow (PBF) changes associated with using 0.018-inch Nickel Titanium (NiTi) as the first alignment archwire during fixed orthodontic treatment.

NCT ID: NCT04376645 Completed - Clinical trials for Orthodontic Appliance

Occlusal Bite Force Changes After Surgical Correction of the Increased Vertical Dimension

Start date: September 1, 2018
Phase: N/A
Study type: Interventional

The aim of this study was to record the OBF changes after surgical correction of mandibular prognathism in patients with or without increased vertical skeletal dimensions at different time intervals (T0: before surgery; T1: at debond; T2: 3 months post-retention).

NCT ID: NCT04375540 Completed - Clinical trials for Orthodontic Treatment

Vertical Gingival Display Changes Associated With Upper Premolars Extraction

Start date: September 1, 2016
Phase: N/A
Study type: Interventional

To investigate and compare vertical gingival display (VGD) changes associated with upper premolars extraction during orthodontic treatment.

NCT ID: NCT04374903 Withdrawn - COVID-19 Patients Clinical Trials

Hydroxychloroquine in Combination With Sirolimus and Dexamethasone for Treating COVID-19 Patients

COVID19-HOPE
Start date: April 1, 2022
Phase: N/A
Study type: Interventional

COVID-19 caused an unprecedented international crisis. There is an urgent need for an effective regimen to cure this illness. Anecdotal data and some prospective results suggested a role of antimalarial drugs (chloroquine and hydroxychloroquine) in the treatment of this disease with best available data showing value of adding azithromycin. Based on drug repurposing studies done by our team and others, we identified the autophagy/apoptosis pathway as a major target for intervention. Based on in-silico and in-vitro models, sirolimus was identified as the drug that deserves urgent prioritization. The rational for combining sirolimus and hydroxychloroquine is explained in details in the study background below and a short video prepared by study PI (https://youtu.be/-zlOMXJp2hg). The evidence for using sirolimus for influenza is emphasized by a RCT that showed reduction of mechanical ventilation time by 50% (7 days on sirolimus arm vs 15 days on oseltamivir/steroids arm). Safe administration in human subjects is illustrated by multiple phase I/II clinical trials, performed in patients with cancer. COVID19-HOPE trial will randomize patients to 2 arms: HCQ/AZ (Arm A) and HCQ/SIR (Arm B). The main inclusion criteria is an RT-PCR test confirming infection with SARS-CoV-2 along with objective clinical criteria of disease (fever, tachypnea and/or hypoxemia). The primary endpoint of study will be Time To Clinical Improvement (TTCI), defined as time from randomization to resolution of the clinical features mentioned above (no fever, no tachypnea and no hypoxemia). In addition, secondary endpoints will include clinical failure by day 28 (need for intubation and/or death), QT interval prolongation, and adverse events. The estimated NNT based on Wilcoxon Mann Whitney comparison of TTCI in study arms is 58 patients (29 each arm). The study includes an adaptive plan, meaning that after different time points the study results will be evaluated and the NNT and randomization scheme (1:1 vs. others) will be evaluated and submitted to the IRB. Also, if one arm proves to be of no value, another regimen might be introduced based on available data. The study will recruit patients for a year and once approved by IRB and JFDA attempts to recruit other centers will be made (including national and regional centers).

NCT ID: NCT04368637 Recruiting - Clinical trials for Acute Myocardial Infarction

Acute Cardiovascular Events Triggered by COVID-19-Related Stress

JoCORE
Start date: May 3, 2020
Phase:
Study type: Observational

The current COVID19 pandemic has afflicted almost the whole globe. The stress related to the pandemic, not the direct virus-related injury, can be potentially associated with acute cardiovascular events due to a large list of physical and psychosocial stresses. This study is a cross sectional study that will enroll patients evaluated during the COVID19 pandemic period for acute cardiovascular events.

NCT ID: NCT04363970 Completed - Urinary Retention Clinical Trials

Early Removal of the Urethral Catheter Following Trans-urethral Resection of Prostate

Start date: June 30, 2019
Phase:
Study type: Observational

Transurethral resection of prostate is the gold standard operation for bladder outflow obstruction due to benign prostatic enlargement. However, catheter removal day is variable. The objective of this study is to compare early and delayed catheter removal groups in terms of, urinary retention after catheter removal, length of hospital stay, weight of resected prostate, duration of resection, peri-operative blood transfusion, and postoperative complications.